FEND for TB
FEND for TB
批准号:
10654567
负责人:
David Alland
金额:
$394.33万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-06-04 至 2025-05-31
关键词:
AccelerationAddressAdultAgeAlgorithmsBacille Calmette-Guerin vaccinationBiological AssayCaringCause of DeathCharacteristicsChildChildhoodChinaClinical ResearchClinical SciencesCollaborationsCommunicable DiseasesCost AnalysisCosts and BenefitsCountryDataDetectionDiabetes MellitusDiagnosisDiagnosticDiagnostic testsDiagnostics ResearchDrug resistanceDrug resistance in tuberculosisEconomicsEnrollmentEnsureEvaluationExposure toFeedbackFoundationsFundingGenus MycobacteriumGood Clinical PracticeHIV InfectionsHealthHealth BenefitHealth systemIndiaLaboratoriesLeadershipLungMalnutritionModelingMultidrug-Resistant TuberculosisMycobacterium tuberculosisOutcomePatient CarePerformancePeruPharmaceutical PreparationsPoliciesPopulationPredispositionPulmonary TuberculosisReadinessReference StandardsResearchResearch DesignResearch PersonnelResistanceSiteSouth AfricaSpecific qualifier valueSpecimenSputumTechnologyTestingTriageTuberculosisTuberculosis diagnosisUgandaUnited States National Institutes of HealthWorkclinical diagnosticsclinical research sitecomorbiditycostcost effectivenessdesigndiagnostic accuracydiagnostic algorithmdiagnostic strategydiagnostic technologieseconomic evaluationexperiencefield studygood laboratory practiceimprovedinnovationinterestlow and middle-income countriesmathematical modelnovelnovel diagnosticsparticipant enrollmentpoint of careprogramsprospectiverecruitresponsesample collectionstatisticstransmission processtuberculosis diagnosticstuberculosis treatment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
In response to RFA-AI-19-030, Feasibility of Novel Diagnostics for TB in Endemic Countries
(FEND-TB) the leadership team has brought together a consortium of experienced investigators
and clinical sites and developed a research plan to address critical unmet TB diagnostic needs.
This program benefits from experience gained during the successful 7-year tenure of the NIH
DMID-funded TB-Clinical Diagnostics Research Consortium (TB-CDRC), with overlap in
leadership, investigators and sites. This program has been adapted in several ways to further
enhance capacity to meet the current challenges in the field -- the successful collaboration with
the Foundation for Innovative New Diagnostics (FIND) has been strengthened to now a full
partnership that will facilitate access to cutting edge technologies and alignment of FEND-TB work
with global stakeholder priorities; clinical study sites in India and Peru have been added to
accelerate recruitment and augment capacity to enroll patients with co-morbidities and drug-
resistance; inclusion of a mature analytic laboratory and revised technology evaluation strategy
that together allow for rational, nimble, step-wise evaluation of early-stage diagnostics; and
inclusion of mathematical modeling capacity to inform optimal diagnostic strategies in TB endemic
settings. This proposal will test two main hypotheses: A. Novel early stage TB diagnostics, that
target bacterial and/or host targets and will be ready for evaluation in the next five years, will have
performance characteristics suitable for point of care (POC)/near-care use for TB detection,
triage, or drug susceptibility testing. B. Rapid non-sputum diagnostics will provide ancillary
support as components of algorithms for the diagnosis of childhood TB as well as paucibacillary
pulmonary TB and extrapulmonary TB in adults. Specific Aims are: 1. To evaluate the diagnostic
accuracy of early stage diagnostic tests for tuberculosis. 2. To identify new early stage
diagnostics for evaluation, and to develop and implement for each a stepwise evaluation plan. 3.
To use economic analysis and transmission modelling to design optimal diagnostic algorithms.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
Diagnostic accuracy of the NOVA Tuberculosis Total Antibody Rapid test for detection of pulmonary tuberculosis and infection with Mycobacterium tuberculosis.
NOVA 结核总抗体快速检测检测肺结核和结核分枝杆菌感染的诊断准确性。
DOI:
10.1016/j.jctube.2023.100362
发表时间:
2023
期刊:
Journal of clinical tuberculosis and other mycobacterial diseases
影响因子:
2
作者:
[Nsubuga,Gideon, Kennedy,Samuel, Rani,Yasha, Hafiz,Zibran, Kim,Soyeon, Ruhwald,Morten, Alland,David, Ellner,Jerrold, Joloba,Moses, Dorman,SusanE, Penn-Nicholson,Adam, Nakiyingi,Lydia]
通讯作者:
Nakiyingi,Lydia
Resources, Workforce Development, and Animal Models for the Rutgers RBL
-
批准号:10793863
-
项目类别:
-
资助金额:$397.07万
-
财政年份:2023
-
负责人:David Alland
-
依托单位:
Supplement to G20AI67347 to complete critical upgrades to the Rutgers RBL
-
批准号:10631469
-
项目类别:
-
资助金额:$191.33万
-
财政年份:2022
-
负责人:David Alland
-
依托单位:
Key Facility Upgrades for the Rutgers University RBL.
-
批准号:10393791
-
项目类别:
-
资助金额:$332.84万
-
财政年份:2021
-
负责人:David Alland
-
依托单位:
Bacterial and Host Heterogeneity in TB latency, persistence and progression
-
批准号:10493254
-
项目类别:
-
资助金额:$265.83万
-
财政年份:2021
-
负责人:David Alland
-
依托单位:
Bacterial and Host Heterogeneity in TB latency, persistence and progression
-
批准号:10665016
-
项目类别:
-
资助金额:$265.83万
-
财政年份:2021
-
负责人:David Alland
-
依托单位:
Bacterial and Host Heterogeneity in TB latency, persistence and progression
-
批准号:10271644
-
项目类别:
-
资助金额:$275.15万
-
财政年份:2021
-
负责人:David Alland
-
依托单位:
Bacterial and Host Heterogeneity in TB latency, persistence and progression
-
批准号:10907954
-
项目类别:
-
资助金额:$33.99万
-
财政年份:2021
-
负责人:David Alland
-
依托单位:
Administrative Core
-
批准号:10493259
-
项目类别:
-
资助金额:$13.8万
-
财政年份:2021
-
负责人:David Alland
-
依托单位:
Administrative Core
-
批准号:10271645
-
项目类别:
-
资助金额:$13.69万
-
财政年份:2021
-
负责人:David Alland
-
依托单位:
Administrative Core
-
批准号:10665018
-
项目类别:
-
资助金额:$13.52万
-
财政年份:2021
-
负责人:David Alland
-
依托单位:
FEND for TB
-
批准号:10180898
-
项目类别:
-
资助金额:$395.47万
-
财政年份:2020
-
负责人:David Alland
-
依托单位:
Genetic, Metabolic and Regulatory Control of MIC and Relapse in M. tuberculosis
-
批准号:10584487
-
项目类别:
-
资助金额:$81.26万
-
财政年份:2020
-
负责人:David Alland
-
依托单位:
Bacteria and Host in TB Transmission
-
批准号:10390418
-
项目类别:
-
资助金额:$181.62万
-
财政年份:2020
-
负责人:David Alland
-
依托单位:
Novel and Optimized Diagnostics for Pediatric TB
-
批准号:10673360
-
项目类别:
-
资助金额:$22.0万
-
财政年份:2020
-
负责人:David Alland
-
依托单位:
Novel and Optimized Diagnostics for Pediatric TB
-
批准号:10905419
-
项目类别:
-
资助金额:$22.0万
-
财政年份:2020
-
负责人:David Alland
-
依托单位:
Bacteria and Host in TB Transmission
-
批准号:10598015
-
项目类别:
-
资助金额:$169.71万
-
财政年份:2020
-
负责人:David Alland
-
依托单位:
FEND for TB
-
批准号:10409690
-
项目类别:
-
资助金额:$416.72万
-
财政年份:2020
-
负责人:David Alland
-
依托单位:
Simple and rapid POC detection for fungemia
-
批准号:10542776
-
项目类别:
-
资助金额:$76.47万
-
财政年份:2020
-
负责人:David Alland
-
依托单位:
FEND for TB
-
批准号:9981978
-
项目类别:
-
资助金额:$399.8万
-
财政年份:2020
-
负责人:David Alland
-
依托单位:
Novel and Optimized Diagnostics for Pediatric TB
-
批准号:10615049
-
项目类别:
-
资助金额:$108.88万
-
财政年份:2020
-
负责人:David Alland
-
依托单位:
海外基金